{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T08:37:25Z","timestamp":1777106245806,"version":"3.51.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Histochem Cell Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immunophenotyping of tumor-infiltrating immune cells is increasingly important for understanding the tumor microenvironment (TME), particularly in the diagnosis and treatment of skin cancer. CD1a\n                    <jats:sup>+<\/jats:sup>\n                    dendritic cells (DC) initiate T\u00a0cell activation by presenting tumor antigens, while T\u00a0cells directly target tumor cells. Analyzing their spatial distribution in different types of skin cancer can provide insights into immune response patterns. To characterize the immune cell composition within the TME, we performed immunofluorescence staining for CD1a and CD3 on formalin-fixed, paraffin-embedded\u00a0(FFPE) samples from actinic keratoses (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200918), squamous cell carcinoma (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200923), basal cell carcinoma (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200919), and melanoma (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200922), with nevi (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200916) and healthy skin (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20099) as controls. Immune cells were quantified across four tumor compartments: intratumoral, tumor margin, intraepidermal, and intradermal. Both CD1a\n                    <jats:sup>+<\/jats:sup>\n                    DC and CD3\n                    <jats:sup>+<\/jats:sup>\n                    T\u00a0cells were detected across all tumor entities, displaying distinct spatial distribution patterns. DC were enriched intratumorally and within the epidermis, whereas T\u00a0cells predominantly accumulated at the tumor margin (main effect of region,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Melanoma exhibited significantly fewer DC at the tumor margin while maintaining strong T\u00a0cell infiltration. Overall, the immune architecture of skin tumors is highly compartmentalized, characterized by region-specific DC and T\u00a0cell distributions. These findings underscore the relevance of spatial immune profiling for understanding immune escape mechanisms and informing immunotherapeutic strategies.\n                  <\/jats:p>","DOI":"10.1007\/s00418-026-02468-8","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:51:21Z","timestamp":1777103481000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Localization of dendritic cells and T\u00a0cells within the tumor microenvironment in different types of skin cancer"],"prefix":"10.1007","volume":"164","author":[{"given":"Marina","family":"Wanner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Ortner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph H.","family":"Tripp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selina","family":"Neurauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Del-Frari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Van Anh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Stoitzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"2468_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40257-022-00731-x","volume":"24","author":"YA Algarin","year":"2023","unstructured":"Algarin YA, Jambusaria-Pahlajani A, Ruiz E, Patel VA (2023) Advances in topical treatments of cutaneous malignancies. Am J Clin Dermatol 24:69\u201380. https:\/\/doi.org\/10.1007\/s40257-022-00731-x","journal-title":"Am J Clin Dermatol"},{"key":"2468_CR2","doi-asserted-by":"publisher","first-page":"9517","DOI":"10.1126\/sciimmunol.adi9517","volume":"9","author":"EG Bawden","year":"2024","unstructured":"Bawden EG, Wagner T, Schr\u00f6der J, Effern M, Hinze D, Newland L, Attrill GH, Lee AR, Engel S, Freestone D, de Lima MM, Gressier E, McBain N, Bachem A, Haque A, Dong R, Ferguson AL, Edwards JJ, Ferguson PM, Scolyer RA, Wilmott JS, Jewell CM, Brooks AG, Gyorki DE, Palendira U, Bedoui S, Waithman J, Hochheiser K, H\u00f6lzel M, Gebhardt T (2024) CD4(+) T\u00a0cell immunity against cutaneous melanoma encompasses multifaceted MHC II-dependent responses. Sci Immunol 9:9517. https:\/\/doi.org\/10.1126\/sciimmunol.adi9517","journal-title":"Sci Immunol"},{"issue":"Suppl 1","key":"2468_CR3","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jaad.2012.09.053","volume":"68","author":"B Berman","year":"2013","unstructured":"Berman B, Cockerell CJ (2013) Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation. J Am Acad Dermatol 68(Suppl 1):S10\u2013S19. https:\/\/doi.org\/10.1016\/j.jaad.2012.09.053","journal-title":"J Am Acad Dermatol"},{"key":"2468_CR4","doi-asserted-by":"publisher","first-page":"1497522","DOI":"10.3389\/fimmu.2024.1497522","volume":"15","author":"M Bida","year":"2024","unstructured":"Bida M, Miya TV, Hull R, Dlamini Z (2024) Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications. Front Immunol 15:1497522. https:\/\/doi.org\/10.3389\/fimmu.2024.1497522","journal-title":"Front Immunol"},{"key":"2468_CR5","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3389\/fimmu.2015.00534","volume":"6","author":"BE Clausen","year":"2015","unstructured":"Clausen BE, Stoitzner P (2015) Functional specialization of skin dendritic cell subsets in regulating T\u00a0cell responses. Front Immunol 6:534. https:\/\/doi.org\/10.3389\/fimmu.2015.00534","journal-title":"Front Immunol"},{"key":"2468_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.molimm.2020.12.006","volume":"130","author":"A de Jong","year":"2021","unstructured":"de Jong A, Ogg G (2021) CD1a function in human skin disease. Mol Immunol 130:14\u201319. https:\/\/doi.org\/10.1016\/j.molimm.2020.12.006","journal-title":"Mol Immunol"},{"key":"2468_CR7","doi-asserted-by":"publisher","first-page":"12596","DOI":"10.3390\/ijms252312596","volume":"25","author":"GAF de Oliveira","year":"2024","unstructured":"de Oliveira GAF, de Oliveira DA, Nisimoto MYSM, Rubinho R, Gomes HC, Marti LC, de Oliveira Filho RS (2024) Advances in tumor-infiltrating lymphocyte (TIL) as a prognostic factor and for treating invasive cutaneous melanoma. Int J Mol Sci 25:12596. https:\/\/doi.org\/10.3390\/ijms252312596","journal-title":"Int J Mol Sci"},{"key":"2468_CR8","doi-asserted-by":"publisher","first-page":"6803756","DOI":"10.1155\/2017\/6803756","volume":"2017","author":"G Dyduch","year":"2017","unstructured":"Dyduch G, Tyrak KE, Glajcar A, Szpor J, Ulatowska-Bia\u0142as M, Oko\u0144 K (2017) Melanomas and dysplastic nevi differ in epidermal CD1c+ dendritic cell count. Biomed Res Int 2017:6803756. https:\/\/doi.org\/10.1155\/2017\/6803756","journal-title":"Biomed Res Int"},{"key":"2468_CR9","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1016\/j.jaad.2021.02.082","volume":"85","author":"DB Eisen","year":"2021","unstructured":"Eisen DB, Asgari MM, Bennett DD, Connolly SM, Dellavalle RP, Freeman EE, Goldenberg G, Leffell DJ, Peschin S, Sligh JE, Wu PA, Frazer-Green L, Malik S, Schlesinger TE (2021) Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol 85:e209\u2013e233. https:\/\/doi.org\/10.1016\/j.jaad.2021.02.082","journal-title":"J Am Acad Dermatol"},{"key":"2468_CR10","doi-asserted-by":"publisher","first-page":"1593806","DOI":"10.1080\/2162402X.2019.1593806","volume":"8","author":"Q Fu","year":"2019","unstructured":"Fu Q, Chen N, Ge C, Li R, Li Z, Zeng B, Li C, Wang Y, Xue Y, Song X, Li H, Li G (2019) Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis. Oncoimmunology 8:1593806. https:\/\/doi.org\/10.1080\/2162402X.2019.1593806","journal-title":"Oncoimmunology"},{"key":"2468_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","volume":"170","author":"C Garbe","year":"2022","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, del Marmol V, Dr\u00e9no B, Fargnoli MC, Forsea AM, Grob JJ, Hoeller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebb\u00e9 C, Lytvynenko B, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stratigos AJ, van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P (2022a) European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment\u2014update 2022. Eur J Cancer 170:256\u2013284. https:\/\/doi.org\/10.1016\/j.ejca.2022.04.018","journal-title":"Eur J Cancer"},{"key":"2468_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejca.2022.03.008","volume":"170","author":"C Garbe","year":"2022","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, del Marmol V, Dr\u00e9no B, Fargnoli MC, Forsea AM, Grob JJ, H\u00f6ller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebb\u00e9 C, Lytvynenko B, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stratigos AJ, van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P (2022b) European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics\u2014update 2022. Eur J Cancer 170:236\u2013255. https:\/\/doi.org\/10.1016\/j.ejca.2022.03.008","journal-title":"Eur J Cancer"},{"key":"2468_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1158\/2326-6066.CIR-24-0421","volume":"13","author":"E Gobbini","year":"2025","unstructured":"Gobbini E, Hubert M, Doffin AC, Eberhardt A, Hermet L, Li D, Duplouye P, Ghamry-Barrin S, Berthet J, Benboubker V, Grimont M, Sakref C, Perrot J, Tondeur G, Harou O, Lopez J, Dubois B, Dalle S, Caux C, Caramel J, Valladeau-Guilemond J (2025) The spatial organization of cDC1 with CD8+ T\u00a0cells is critical for the response to immune checkpoint inhibitors in patients with melanoma. Cancer Immunol Res 13:517\u2013526. https:\/\/doi.org\/10.1158\/2326-6066.CIR-24-0421","journal-title":"Cancer Immunol Res"},{"key":"2468_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jdermsci.2014.08.012","volume":"77","author":"M Haniffa","year":"2015","unstructured":"Haniffa M, Gunawan M, Jardine L (2015) Human skin dendritic cells in health and disease. J Dermatol Sci 77:85\u201392. https:\/\/doi.org\/10.1016\/j.jdermsci.2014.08.012","journal-title":"J Dermatol Sci"},{"key":"2468_CR15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12943-023-01854-3","volume":"22","author":"N Hasan","year":"2023","unstructured":"Hasan N, Nadaf A, Imran M, Jiba U, Sheikh A, Almalki WH, Almujri SS, Mohammed YH, Kesharwani P, Ahmad FJ (2023) Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches. Mol Cancer 22:168. https:\/\/doi.org\/10.1186\/s12943-023-01854-3","journal-title":"Mol Cancer"},{"key":"2468_CR16","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1001\/jama.2025.13074","volume":"334","author":"UM Joshi","year":"2025","unstructured":"Joshi UM, Kashani-Sabet M, Kirkwood JM (2025) Cutaneous melanoma: a review. JAMA 334:2113\u20132125. https:\/\/doi.org\/10.1001\/jama.2025.13074","journal-title":"JAMA"},{"key":"2468_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41568-022-00442-9","volume":"22","author":"S Kalaora","year":"2022","unstructured":"Kalaora S, Nagler A, Wargo JA, Samuels Y (2022) Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer 22:195\u2013207. https:\/\/doi.org\/10.1038\/s41568-022-00442-9","journal-title":"Nat Rev Cancer"},{"key":"2468_CR18","doi-asserted-by":"publisher","DOI":"10.2174\/0113816128341628250519093548","author":"F Kreidieh","year":"2025","unstructured":"Kreidieh F, Wong MK (2025) New standards in the treatment of advanced metastatic melanoma: immunotherapy and BRAF-targeted therapies as emerging paradigms. Curr Pharm des. https:\/\/doi.org\/10.2174\/0113816128341628250519093548","journal-title":"Curr Pharm des"},{"key":"2468_CR19","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00262-007-0286-3","volume":"56","author":"A Lad\u00e1nyi","year":"2007","unstructured":"Lad\u00e1nyi A, Kiss J, Somlai B, Gilde K, Fej\u0151s Z, Mohos A, Gaudi I, T\u00edm\u00e1r J (2007) Density of DC-LAMP+ mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 56:1459\u20131469. https:\/\/doi.org\/10.1007\/s00262-007-0286-3","journal-title":"Cancer Immunol Immunother"},{"key":"2468_CR20","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.3390\/ijms22083849","volume":"22","author":"YI Lee","year":"2021","unstructured":"Lee YI, Choi S, Roh WS, Lee JH, Kim T-G (2021) Cellular senescence and inflammaging in the skin microenvironment. Int J Mol Sci 22:3849. https:\/\/doi.org\/10.3390\/ijms22083849","journal-title":"Int J Mol Sci"},{"key":"2468_CR21","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/ddg.14072","volume":"18","author":"U Leiter","year":"2020","unstructured":"Leiter U, Heppt MV, Steeb T, Amaral T, Bauer A, Becker JC, Breitbart E, Breuninger H, Diepgen T, Dirschka T, Eigentler T, Flaig M, Follmann M, Fritz K, Greinert R, Gutzmer R, Hillen U, Ihrler S, John SM, Kolbl O, Kraywinkel K, Loser C, Nashan D, Noor S, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Welzel J, Wermker K, Garbe C, Berking C (2020) S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC)\u2014short version, Part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational disease. J Dtsch Dermatol Ges 18:400\u2013413. https:\/\/doi.org\/10.1111\/ddg.14072","journal-title":"J Dtsch Dermatol Ges"},{"key":"2468_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41571-024-00984-x","volume":"22","author":"M Lopez de Rodas","year":"2025","unstructured":"Lopez de Rodas M, Villalba-Esparza M, Sanmamed MF, Chen L, Rimm DL, Schalper KA (2025) Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach. Nat Rev Clin Oncol 22:163\u2013181. https:\/\/doi.org\/10.1038\/s41571-024-00984-x","journal-title":"Nat Rev Clin Oncol"},{"key":"2468_CR23","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3389\/fimmu.2020.02105","volume":"11","author":"F Maibach","year":"2020","unstructured":"Maibach F, Sadozai H, Seyed Jafari SM, Hunger RE, Schenk M (2020) Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front Immunol 11:2105. https:\/\/doi.org\/10.3389\/fimmu.2020.02105","journal-title":"Front Immunol"},{"key":"2468_CR24","doi-asserted-by":"publisher","first-page":"980709","DOI":"10.3389\/fimmu.2022.980709","volume":"13","author":"G Mestrallet","year":"2022","unstructured":"Mestrallet G, Sone K, Bhardwaj N (2022) Strategies to overcome DC dysregulation in the tumor microenvironment. Front Immunol 13:980709. https:\/\/doi.org\/10.3389\/fimmu.2022.980709","journal-title":"Front Immunol"},{"key":"2468_CR25","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3390\/cells13191615","volume":"13","author":"AM Mousa","year":"2024","unstructured":"Mousa AM, Enk AH, Hassel JC, Reschke R (2024) Immune checkpoints and cellular landscape of the tumor microenvironment in non-melanoma skin cancer (NMSC). Cells 13:1615. https:\/\/doi.org\/10.3390\/cells13191615","journal-title":"Cells"},{"key":"2468_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.14740\/wjon1349","volume":"12","author":"PP Naik","year":"2021","unstructured":"Naik PP (2021) Cutaneous malignant melanoma: a review of early diagnosis and management. World J Oncol 12:7\u201319. https:\/\/doi.org\/10.14740\/wjon1349","journal-title":"World J Oncol"},{"key":"2468_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113254","author":"K Peris","year":"2023","unstructured":"Peris K, Fargnoli MC, Kaufmann R, Arenberger P, Bastholt L, Seguin NB, Bataille V, Brochez L, del Marmol V, Dummer R, Forsea AM, Gaudy-Marqueste C, Harwood CA, Hauschild A, H\u00f6ller C, Kandolf L, Kelleners-Smeets NWJ, Lallas A, Leiter U, Malvehy J, Marinovi\u0107 B, Mijuskovic Z, Moreno-Ramirez D, Nagore E, Nathan P, Stratigos AJ, Stockfleth E, Tagliaferri L, Trakatelli M, Vieira R, Zalaudek I, Garbe C (2023) European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma\u2014update 2023. Eur J Cancer. https:\/\/doi.org\/10.1016\/j.ejca.2023.113254","journal-title":"Eur J Cancer"},{"key":"2468_CR28","doi-asserted-by":"publisher","first-page":"114099","DOI":"10.1016\/j.ejca.2024.114099","volume":"205","author":"SK Petersen","year":"2024","unstructured":"Petersen SK, Hansen CR, Ellebaek E, Schmidt H, Haslund CA, Ruhlmann CH, Bastholt L (2024) Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study. Eur J Cancer 205:114099. https:\/\/doi.org\/10.1016\/j.ejca.2024.114099","journal-title":"Eur J Cancer"},{"key":"2468_CR29","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3389\/fimmu.2020.00364","volume":"11","author":"I Plesca","year":"2020","unstructured":"Plesca I, Tunger A, M\u00fcller L, Wehner R, Lai X, Grimm MO, Rutella S, Bachmann M, Schmitz M (2020) Characteristics of tumor-infiltrating lymphocytes prior to and during immune checkpoint inhibitor therapy. Front Immunol 11:364. https:\/\/doi.org\/10.3389\/fimmu.2020.00364","journal-title":"Front Immunol"},{"key":"2468_CR30","doi-asserted-by":"publisher","first-page":"8745863","DOI":"10.1155\/2020\/8745863","volume":"2020","author":"J Pogorzelska-Dyrbu\u015b","year":"2020","unstructured":"Pogorzelska-Dyrbu\u015b J, Szepietowski JC (2020) Density of Langerhans cells in nonmelanoma skin cancers: a systematic review. Mediators Inflamm 2020:8745863. https:\/\/doi.org\/10.1155\/2020\/8745863","journal-title":"Mediators Inflamm"},{"key":"2468_CR31","doi-asserted-by":"publisher","first-page":"e000832","DOI":"10.1136\/jitc-2020-000832","volume":"9","author":"A Prokopi","year":"2021","unstructured":"Prokopi A, Tripp CH, Tummers B, Hornsteiner F, Spoeck S, Crawford JC, Clements DR, Efremova M, Hutter K, Bellmann L, Cappellano G, Cadilha BL, Kobold S, Boon L, Ortner D, Trajanoski Z, Chen S, de Gruijl TD, Idoyaga J, Green DR, Stoitzner P (2021) Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy. J Immunother Cancer 9:e000832. https:\/\/doi.org\/10.1136\/jitc-2020-000832","journal-title":"J Immunother Cancer"},{"key":"2468_CR32","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s12032-025-03002-x","volume":"42","author":"N Ravi","year":"2025","unstructured":"Ravi N, Tye GJ, Dhaliwal SS, Musa MY, Wong MTJ, Lai NS (2025) Immune profiling in oncology: bridging the gap between technology and treatment. Med Oncol 42:446. https:\/\/doi.org\/10.1007\/s12032-025-03002-x","journal-title":"Med Oncol"},{"key":"2468_CR33","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.abd.2019.10.004","volume":"94","author":"CPH Reinehr","year":"2019","unstructured":"Reinehr CPH, Bakos RM (2019) Actinic keratoses: review of clinical, dermoscopic, and therapeutic aspects. An Bras Dermatol 94:637\u2013657. https:\/\/doi.org\/10.1016\/j.abd.2019.10.004","journal-title":"An Bras Dermatol"},{"key":"2468_CR34","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","volume":"25","author":"M Roerden","year":"2025","unstructured":"Roerden M, Spranger S (2025) Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat Rev Immunol 25:353\u2013369. https:\/\/doi.org\/10.1038\/s41577-024-01111-8","journal-title":"Nat Rev Immunol"},{"key":"2468_CR35","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.0105-2896.2009.00886.x","volume":"234","author":"N Romani","year":"2010","unstructured":"Romani N, Clausen BE, Stoitzner P (2010) Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunol Rev 234:120\u2013141. https:\/\/doi.org\/10.1111\/j.0105-2896.2009.00886.x","journal-title":"Immunol Rev"},{"key":"2468_CR36","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1111\/j.1365-4632.2008.03808.x","volume":"47","author":"MO Rybka","year":"2008","unstructured":"Rybka MO, Cintra ML, de Souza EM, Metze K (2008) Density of dendritic cells around basal cell carcinomas is related to tumor size, anatomical site and stromal characteristics, and might be responsible for the response to topical therapy. Int J Dermatol 47:1240\u20131244. https:\/\/doi.org\/10.1111\/j.1365-4632.2008.03808.x","journal-title":"Int J Dermatol"},{"key":"2468_CR37","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00011-022-01598-8","volume":"71","author":"A Salminen","year":"2022","unstructured":"Salminen A, Kaarniranta K, Kauppinen A (2022) Photoaging: UV radiation-induced inflammation and immunosuppression accelerate the aging process in the skin. Inflamm Res 71:817\u2013831. https:\/\/doi.org\/10.1007\/s00011-022-01598-8","journal-title":"Inflamm Res"},{"key":"2468_CR38","doi-asserted-by":"publisher","first-page":"1382842","DOI":"10.3389\/fimmu.2024.1382842","volume":"15","author":"M Sang","year":"2024","unstructured":"Sang M, Ge J, Ge J, Tang G, Wang Q, Wu J, Mao L, Ding X, Zhou X (2024) Immune regulatory genes impact the hot\/cold tumor microenvironment, affecting cancer treatment and patient outcomes. Front Immunol 15:1382842. https:\/\/doi.org\/10.3389\/fimmu.2024.1382842","journal-title":"Front Immunol"},{"key":"2468_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2188\/jea.JE20160166","volume":"28","author":"I Savoye","year":"2018","unstructured":"Savoye I, Olsen CM, Whiteman DC, Bijon A, Wald L, Dartois L, Clavel-Chapelon F, Boutron-Ruault MC, Kvaskoff M (2018) Patterns of ultraviolet radiation exposure and skin cancer risk: the E3N-SunExp study. J Epidemiol 28:27\u201333. https:\/\/doi.org\/10.2188\/jea.JE20160166","journal-title":"J Epidemiol"},{"key":"2468_CR40","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/ddg.14580","volume":"19","author":"M Seidl-Philipp","year":"2021","unstructured":"Seidl-Philipp M, Frischhut N, H\u00f6llweger N, Schmuth M, Nguyen VA (2021) Known and new facts on basal cell carcinoma. JDDG 19:1021\u20131041. https:\/\/doi.org\/10.1111\/ddg.14580","journal-title":"JDDG"},{"key":"2468_CR41","doi-asserted-by":"publisher","first-page":"721409","DOI":"10.3389\/fimmu.2021.721409","volume":"12","author":"F Shi","year":"2021","unstructured":"Shi F, Zhang W, Yang Y, Yang Y, Zhao J, Xie M, Sheng C, Wang S, Wang Q (2021) Sex disparities of genomic determinants in response to immune checkpoint inhibitors in melanoma. Front Immunol 12:721409. https:\/\/doi.org\/10.3389\/fimmu.2021.721409","journal-title":"Front Immunol"},{"key":"2468_CR42","doi-asserted-by":"publisher","first-page":"6778","DOI":"10.3390\/ijms26146778","volume":"26","author":"H Sikorski","year":"2025","unstructured":"Sikorski H, \u017bmijewski MA, Piotrowska A (2025) Tumor microenvironment in melanoma\u2014characteristic and clinical implications. Int J Mol Sci 26:6778. https:\/\/doi.org\/10.3390\/ijms26146778","journal-title":"Int J Mol Sci"},{"key":"2468_CR43","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.3390\/cancers15082206","volume":"15","author":"E Sosa Cuevas","year":"2023","unstructured":"Sosa Cuevas E, Saas P, Aspord C (2023) Dendritic cell subsets in melanoma: pathophysiology, clinical prognosis and therapeutic exploitation. Cancers (Basel) 15:2206. https:\/\/doi.org\/10.3390\/cancers15082206","journal-title":"Cancers (Basel)"},{"key":"2468_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/3-540-32636-7_2","volume":"311","author":"RM Steinman","year":"2006","unstructured":"Steinman RM, Hemmi H (2006) Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 311:17\u201358. https:\/\/doi.org\/10.1007\/3-540-32636-7_2","journal-title":"Curr Top Microbiol Immunol"},{"key":"2468_CR45","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay C, Tanaka A, Sakaguchi S (2023) Tumor-infiltrating regulatory T\u00a0cells as targets of cancer immunotherapy. Cancer Cell 41:450\u2013465. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.014","journal-title":"Cancer Cell"},{"key":"2468_CR46","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1158\/2326-6066.CIR-17-0110","volume":"5","author":"M van den Hout","year":"2017","unstructured":"van den Hout M, Koster BD, Sluijter BJR, Molenkamp BG, van de Ven R, van den Eertwegh AJM, Scheper RJ, van Leeuwen PAM, van den Tol MP, de Gruijl TD (2017) Melanoma sequentially suppresses different DC subsets in the sentinel lymph node, affecting disease spread and recurrence. Cancer Immunol Res 5:969\u2013977. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0110","journal-title":"Cancer Immunol Res"},{"key":"2468_CR47","doi-asserted-by":"publisher","first-page":"114190","DOI":"10.1016\/j.ejca.2024.114190","volume":"208","author":"IAJ van Duin","year":"2024","unstructured":"van Duin IAJ, Schuiveling M, ter Maat LS, van Amsterdam WAC, van den Berkmortel F, Boers-Sonderen M, de Groot JWB, Hospers GAP, Kapiteijn E, Labots M, Piersma D, Schrader AMR, Vreugdenhil G, Westgeest H, Veta M, Blokx WAM, van Diest PJ, Suijkerbuijk KPM (2024) Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma. Eur J Cancer 208:114190. https:\/\/doi.org\/10.1016\/j.ejca.2024.114190","journal-title":"Eur J Cancer"},{"key":"2468_CR48","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/14737159.2024.2312102","volume":"24","author":"GM Vargas","year":"2024","unstructured":"Vargas GM, Shafique N, Xu X, Karakousis G (2024) Tumor-infiltrating lymphocytes as a prognostic and predictive factor for melanoma. Expert Rev Mol Diagn 24:299\u2013310. https:\/\/doi.org\/10.1080\/14737159.2024.2312102","journal-title":"Expert Rev Mol Diagn"},{"key":"2468_CR49","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/path.1344","volume":"200","author":"W Vermi","year":"2003","unstructured":"Vermi W, Bonecchi R, Facchetti F, Bianchi D, Sozzani S, Festa S, Berenzi A, Cella M, Colonna M (2003) Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 200:255\u2013268. https:\/\/doi.org\/10.1002\/path.1344","journal-title":"J Pathol"},{"key":"2468_CR50","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cancers17111769","volume":"17","author":"V-M Voiculescu","year":"2025","unstructured":"Voiculescu V-M, Popescu A-I, Costache M (2025) Immunohistochemistry for skin cancers: new insights into diagnosis and treatment of melanoma. Cancers (Basel) 17:1769. https:\/\/doi.org\/10.3390\/cancers17111769","journal-title":"Cancers (Basel)"},{"key":"2468_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24183214","author":"S Wang","year":"2019","unstructured":"Wang S, Cowley LA, Liu XS (2019) Sex differences in cancer immunotherapy efficacy, biomarkers, and therapeutic strategy. Molecules. https:\/\/doi.org\/10.3390\/molecules24183214","journal-title":"Molecules"},{"key":"2468_CR52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG, Postow MA, Gaudy-Marqueste C, Medina T, Lao CD, Walker J, M\u00e1rquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Sch\u00f6ffski P, Carlino MS, Sandhu S, Lebb\u00e9 C, Ascierto PA, Long GV, Ritchings C, Nassar A, Askelson M, Benito MP, Wang W, Hodi FS, Larkin J (2025) Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 392:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2407417","journal-title":"N Engl J Med"},{"key":"2468_CR53","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1056\/NEJMra2206348","volume":"388","author":"A Wysong","year":"2023","unstructured":"Wysong A (2023) Squamous-cell carcinoma of the skin. N Engl J Med 388:2262\u20132273. https:\/\/doi.org\/10.1056\/NEJMra2206348","journal-title":"N Engl J Med"},{"key":"2468_CR54","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41568-024-00680-z","volume":"24","author":"T Xiao","year":"2024","unstructured":"Xiao T, Lee J, Gauntner TD, Velegraki M, Lathia JD, Li Z (2024) Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications. Nat Rev Cancer 24:338\u2013355. https:\/\/doi.org\/10.1038\/s41568-024-00680-z","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2468_CR540","doi-asserted-by":"publisher","first-page":"8151","DOI":"10.1038\/s41467-025-62878-5","volume":"16","author":"J Yang","year":"2025","unstructured":"Yang J, Wang C, Fu D, Ho LL, Galani K, Chen L, Gonzalez J, Fu J, Huang AY, Frederick DT, He L, Asnani M, Tacke R, Robitschek EJ, Yadav SK, Deng W, Burke KP, Sharova T, Sullivan RJ, Weiss S, Rai K, Liu D, Boland GM, Kellis M. Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma. Nat Commun. 2025 16(1):8151. https:\/\/doi.org\/10.1038\/s41467-025-62878-5","journal-title":"Nat Commun"},{"key":"2468_CR55","doi-asserted-by":"publisher","first-page":"5996","DOI":"10.1038\/s41598-025-90485-3","volume":"15","author":"L Zhou","year":"2025","unstructured":"Zhou L, Zhong Y, Han L, Xie Y, Wan M (2025) Global, regional, and national trends in the burden of melanoma and non-melanoma skin cancer: insights from the global burden of disease study 1990\u20132021. Sci Rep 15:5996. https:\/\/doi.org\/10.1038\/s41598-025-90485-3","journal-title":"Sci Rep"}],"container-title":["Histochemistry and Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00418-026-02468-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00418-026-02468-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00418-026-02468-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:51:22Z","timestamp":1777103482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00418-026-02468-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2468"],"URL":"https:\/\/doi.org\/10.1007\/s00418-026-02468-8","relation":{},"ISSN":["1432-119X"],"issn-type":[{"value":"1432-119X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Artificial intelligence (ChatGPT-4o, OpenAI, San Francisco, CA, USA) was used for linguistic optimization, grammar correction, and structural editing without altering the scientific content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Editorial assistance"}},{"value":"WM has received, independent of this study, congress and travel support from BMS, UCB, AbbVie, and Sanofi. NVA has received, independent of this study, honoraria from Amgen, BMS, GSK, MSD, Merck, Novartis, Pierre Fabre, Roche, and Sanofi; has served in consulting or advisory roles for Amgen, BMS, MSD, Merck, Novartis, Pierre Fabre, Roche, and Sanofi; has received travel reimbursements from AstraZeneca, BMS, Novartis, Pierre Fabre, Roche, and Sanofi; and serves on the steering committee of Novartis. BA, OD, TCH, HM, NS, DFB, and PS declare no conflicts of interest related to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"28"}}